Neo-adjuvant trastuzumab-based chemotherapy might also optimise the interactions between the tumour and the host’s immune system, especially CD8+ T-cells among the others,18 and also enhance trastuzumab-induced ADCC (antibody-dependent cellular cytotoxicity).19 This evidence concerns the gene CD8A and neoplasm.